Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
Angela W. Dymond; Paul Martin; Karen So; Yifan Huang; Paul Severin; Victoria Holmes; Gabriella Mariani; Thomas Marbury
